Evidence map›Paper›PMID 39649245›Full record

ArticleJournal of hepatocellular carcinoma2024

m

Wenchuan Li, Min Zeng, Yuanjia Ning, Rongzhou Lu, Yunyu Wei, Zuoming Xu, Huamei Wei, Jian Pu

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. The mFrontiers in oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenchuan Li *Guangxi Clinical Medical Research Center for Hepatobiliary Diseases, Baise, People's Republic of China.
Min Zeng *Graduate College of Youjiang Medical University for Nationalities, Baise, People's Republic of China.
Yuanjia Ning *Graduate College of Youjiang Medical University for Nationalities, Baise, People's Republic of China.
Rongzhou LuGraduate College of Youjiang Medical University for Nationalities, Baise, People's Republic of China.
Yunyu WeiGraduate College of Youjiang Medical University for Nationalities, Baise, People's Republic of China.
Zuoming XuDepartment of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, People's Republic of China.
Huamei WeiGuangxi Clinical Medical Research Center for Hepatobiliary Diseases, Baise, People's Republic of China.
Jian PuGuangxi Clinical Medical Research Center for Hepatobiliary Diseases, Baise, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Hepatocellular carcinoma (HCC) is one of the most lethal malignancies in the world. Oncofetal proteins are the optimal diagnostic biomarkers and therapeutic targets for HCC. As the most abundant modification in RNA, N Methods: Gene expression in HCC tissues and cells was detected using qPCR. The level of m Results: NUTM2B-AS1 was identified as a novel oncofetal long noncoding RNA that was upregulated in the fetal liver and HCC and silenced in adult liver tissues. METTL3 and METTL16 induce m Conclusion: METTL3- and METTL16-mediated m

Indexed as

hepatocellular carcinomahistone modificationN6-methyladenosineoncofetal moleculestemness

Identifiers

PMID39649245
PMCPMC11624692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.